Zusammenfassung
Kardiovaskuläre Erkrankungen haben die höchste Prävalenz im fortgeschrittenen Lebensalter. Trotzdem sind höhere Altersgruppen in Randomized Controlled Trials (RCT) häufig unterrepräsentiert. Die Folge ist eine in vielen Fällen ungenügende Evidenz. Empfehlungen aus Leitlinien können daher nur bedingt auf diese Altersgruppe übertragen werden. Aufgrund der Komplexität und Vulnerabilität geriatrischer Patienten bedarf es häufig individueller Überlegungen in der pharmakologischen Therapie. Im vorliegenden Beitrag wird die Pharmakotherapie einiger relevanter kardiovaskulärer Erkrankungen aus der Perspektive eines geriatrischen Behandlungsansatzes diskutiert.
Abstract
Cardiovascular diseases have the highest prevalence in advanced age. Nevertheless, older age groups are frequently underrepresented in randomized controlled trials (RCT). Consequently, in many cases the evidence is often insufficient. Therefore, recommendations from guidelines can only be transferred to this age group to a limited extent. Due to the complexity and vulnerability of geriatric patients, individual considerations in pharmacological therapy are often required. In the following article, the pharmacotherapy of some relevant cardiovascular diseases is discussed from the perspective of a geriatric treatment approach.
Literatur
Rottlaender D, Scherner M, Schneider T, Erdmann E (2007) Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr 132(4):139–144
Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P (2012) Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. Plos One 7(3):e33559
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156
Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, Group HS (2008) Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 168(17):1890–1896
Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136–147
Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63(2):177–186
Weingart C, Wirnsberger GH (2021) Clinical implications of the estimated glomerular filtration rate. Z Gerontol Geriatr 54(3):205–210
Gosch MHH (2014) Pharmakotherapie. In: Pantel S, Bollheimer, Sieber, Kruse (Hrsg) Praxishandbuch Altersmedizin. Kohlhammer, Stuttgart, S 642–650
Chudiak A, Uchmanowicz I, Mazur G (2018) Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging 13:1409–1418
Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860
Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303(9):841–848
Bibbins-Domingo K, Force USPST (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 164(12):836–845
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al (2019) ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 140(11):e596–e646
Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA (2022) Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 327(16):1585–1597
Muhlbauer V, Dallmeier D, Brefka S, Bollig C, Voigt-Radloff S, Denkinger M (2019) The pharmacological treatment of arterial hypertension in frail, older patients—a systematic review. Dtsch Arztebl Int 116(3):23–30
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358(18):1887–1898
Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 〉/=75 years: a randomized clinical trial. JAMA 315(24):2673–2682
Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N et al (2015) No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 13:78
Welsh TJ, Gordon AL, Gladman JRF (2019) Treatment of hypertension in people with dementia: a multicenter prospective observational cohort study. J Am Med Dir Assoc 20(9):1111–1115
Freund TGB, Jeschke E (2016) Qualität der poststationären Arzneimittelversorgung von Patienten mit Herzinsuffizienz. In: Klauber JGM, friedirch J, Wasem J (Hrsg) Krankenhaus-Report. Schattauer, Stuttgart, S 229–246
Aronow WS, Ahn C, Kronzon I (1998) Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest 113(4):867–869
Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH (2013) The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 24(10):2649–2657
Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D et al (2021) Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: data from the EMPA-REG OUTCOME trial. J Card Fail 27(8):888–895
Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ et al (2021) Effect of Empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation 144(16):1284–1294
Bruno N, Sinagra G, Paolillo S, Bonomi A, Corra U, Piepoli M et al (2018) Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. ESC Heart Fail 5(3):267–274
Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215):1575–1581
Dulin BR, Krum H (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 21(4):393–399
Gilstrap L, Zipkin RJ, Barnes JA, King A, O’Malley AJ, Gaziano TA et al (2022) Sacubitril/valsartan vs. ACEi/ARB at hospital discharge and 5‑year survival in older patients with heart failure with reduced ejection fraction: a decision analysis approach. Am Heart J 250:23–28. https://doi.org/10.1016/j.ahj.2022.04.007
Veenis JF, Brunner-La RHP, Linssen GC, Geerlings PR, Van Gent MW, Aksoy I et al (2019) Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. Eur J Prev Cardiol 26(13):1399–1407
Komajda M, Schope J, Wagenpfeil S, Tavazzi L, Bohm M, Ponikowski P et al (2019) Physicians’ guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 21(7):921–929
Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696
Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125(19):2298–2307
Akishita M, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T et al (2022) Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. Arch Gerontol Geriatr 101:104661
Kim D, Yang PS, Sung JH, Jang E, Yu HT, Kim TH et al (2022) Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke 53(6):1873–1882. https://doi.org/10.1161/STROKEAHA.121.036757
Shah SJ, Singer DE, Fang MC, Reynolds K, Go AS, Eckman MH (2019) Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circ Cardiovasc Qual Outcomes 12(11):e6212
Gosch M, Iglseder B, Heppner HJ (2016) Falls and dementia are not contraindications for anticoagulation in older adults with atrial fibrillation. Z Gerontol Geriatr 49(5):458–459
Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J (2016) New oral anticoagulants for prophylaxis of stroke. Results of an expert conference on practical use in geriatric patients. Z Gerontol Geriatr 49(3):216–226
Feeney JM, Santone E, DiFiori M, Kis L, Jayaraman V, Montgomery SC (2016) Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: a TQIP study. J Trauma Acute Care Surg 81(5:843–848
Feeney JM, Neulander M, DiFiori M, Kis L, Shapiro DS, Jayaraman V et al (2017) Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma. Injury 48(1):47–50
Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Gosch gibt an, Vortrags- bzw. Beraterhonorare von Bayer, BMS, Böhringer, Daiichi Sankyo, Hexal, Novartis, Pfizer erhalten zu haben.
Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Gosch, M. Pharmakologische Therapie kardiologischer Erkrankungen im Alter. Z Gerontol Geriat 55, 471–475 (2022). https://doi.org/10.1007/s00391-022-02084-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00391-022-02084-w